Axon Enterprise’s (AXON) “Overweight” Rating Reaffirmed at Piper Sandler

Piper Sandler reissued their overweight rating on shares of Axon Enterprise (NASDAQ:AXON) in a report published on Friday morning, MarketBeat.com reports. The firm currently has a $540.00 price objective on the biotechnology company’s stock, down from their prior price objective of $561.00.

Several other research analysts have also recently weighed in on AXON. Needham & Company LLC lowered their price target on shares of Axon Enterprise from $750.00 to $500.00 and set a “buy” rating on the stock in a research report on Friday. Weiss Ratings restated a “hold (c-)” rating on shares of Axon Enterprise in a research report on Tuesday. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Barclays lifted their target price on shares of Axon Enterprise from $523.00 to $688.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, Northcoast Research boosted their target price on shares of Axon Enterprise from $650.00 to $680.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Thirteen equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, Axon Enterprise currently has a consensus rating of “Moderate Buy” and an average target price of $631.35.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON traded down $69.56 during midday trading on Friday, hitting $313.00. The company had a trading volume of 5,224,684 shares, compared to its average volume of 975,165. Axon Enterprise has a twelve month low of $307.00 and a twelve month high of $665.07. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.15 and a quick ratio of 1.80. The stock has a market cap of $25.43 billion, a price-to-earnings ratio of 100.32, a price-to-earnings-growth ratio of 8.09 and a beta of 1.48. The business’s 50-day simple moving average is $441.53 and its 200-day simple moving average is $475.20.

Axon Enterprise (NASDAQ:AXON) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.89 by ($0.17). The company had revenue of $908.55 million for the quarter, compared to analyst estimates of $934.33 million. Axon Enterprise had a return on equity of 2.84% and a net margin of 6.19%. The business’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period last year, the firm posted $1.17 EPS. On average, research analysts predict that Axon Enterprise will post 2.10 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Isaiah Fields sold 1,017 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $480.45, for a total transaction of $488,617.65. Following the completion of the transaction, the insider directly owned 56,264 shares in the company, valued at approximately $27,032,038.80. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, President Joshua Isner sold 16,775 shares of the stock in a transaction on Monday, August 31st. The stock was sold at an average price of $574.43, for a total value of $9,636,063.25. Following the transaction, the president owned 296,974 shares of the company’s stock, valued at approximately $170,590,774.82. This represents a 5.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 37,397 shares of company stock worth $21,234,034. Company insiders own 4.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of AXON. Keel Point LLC lifted its holdings in shares of Axon Enterprise by 4.4% in the 1st quarter. Keel Point LLC now owns 599 shares of the biotechnology company’s stock worth $254,000 after acquiring an additional 25 shares during the last quarter. Bridgewater Advisors Inc. increased its holdings in Axon Enterprise by 4.4% in the 2nd quarter. Bridgewater Advisors Inc. now owns 616 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 26 shares during the last quarter. Pinnacle Wealth Planning Services Inc. increased its holdings in Axon Enterprise by 7.8% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 361 shares of the biotechnology company’s stock valued at $153,000 after purchasing an additional 26 shares during the last quarter. Roman Butler Fullerton & Co. increased its holdings in Axon Enterprise by 2.4% in the 1st quarter. Roman Butler Fullerton & Co. now owns 1,278 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 30 shares during the last quarter. Finally, 44 Wealth Management LLC raised its position in Axon Enterprise by 6.0% in the first quarter. 44 Wealth Management LLC now owns 530 shares of the biotechnology company’s stock valued at $225,000 after purchasing an additional 30 shares during the period. Hedge funds and other institutional investors own 79.08% of the company’s stock.

Key Axon Enterprise News

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q3 revenue reached a record $909 million, up 28% year over year, while software and services revenue rose 43%. Axon also reported AI annual recurring revenue above $100 million, signaling continued demand for its software and AI offerings. Axon Q3 results
• Neutral Sentiment: Axon committed an additional $1.2 billion to drone maker Skydio, bringing its stake to 37% and making it Skydio’s exclusive public-safety distributor in the U.S. and Canada. The move could expand Axon’s Drone as First Responder business, but its scale also raises investment and execution risks. Reuters: Axon invests in Skydio
• Negative Sentiment: Q3 adjusted earnings of $1.72 per share and revenue of $908.55 million fell short of analyst expectations. Axon’s 2026 revenue forecast was reduced to $3.6 billion from a consensus of about $3.7 billion; its Q4 revenue guidance also came in below estimates. The company cited delays in federal counter-drone projects, while margin pressure added to concerns. Zacks: Q3 miss and outlook
• Negative Sentiment: Several analysts lowered price targets after the results, and Craig Hallum downgraded AXON from Buy to Hold, adding to pressure on investor sentiment. Benzinga: analyst forecast changes
• Negative Sentiment: A class-action lawsuit over Axon’s license-plate surveillance practices is a potential additional legal and reputational overhang. Class-action announcement

Axon Enterprise Company Profile

Axon Enterprise develops technology and services for public safety agencies. Its products include TASER conducted-energy weapons, body-worn and in-car cameras, and related hardware designed to support law enforcement and other safety professionals.

The company also provides cloud-based software for managing digital evidence, records and operational workflows. Its Axon Evidence platform helps agencies store, organize and share video and other evidence, while its broader software offerings include tools for dispatch and records management.

Founded in 1993 as TASER International, the company adopted the name Axon Enterprise in 2017 as it expanded beyond conducted-energy weapons into connected devices and software.